MAM
PGNX

Morse Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Morse Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,400
Closed -$113K – 145
2017
Q3 		$113K Sell
15,400
-1,000
-6% -$6.35K 0.03% 128
2017
Q2 		$111K Hold
16,400
– – 0.04% 122
2017
Q1 		$155K Buy
+16,400
New +$164K 0.05% 132

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

Morse Asset Management's PGNX Position: Q4 2017 in Review

Morse Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 15,400 shares — an estimated $113K sold.

Morse Asset Management first reported a position in PGNX in Q1 2017 and held it in 3 quarters. The position peaked at $155K in Q1 2017. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • Morse Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Morse Asset Management sold 15,400 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $113K.
  • Morse Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 3 quarters.
  • Morse Asset Management's Progenics Pharmaceuticals Inc position peaked at $155K in Q1 2017.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on Morse Asset Management's 13F filing for Q4 2017, filed 29 Jan 2018.